The determinants of plasma plasminogen activator inhibitor-1 levels differ for American and Japanese men aged 40-49

Diabetes Research and Clinical Practice

Volumn 72, Issue 2, 2006, Pages 176-182

  Takamiya, Tomoko ^a   Kadowaki, Takashi ^a,b   Zaky, Wahid R ^a   Ueshima, Hirotsugu ^b   Evans, Rhobert W ^a   Okamura, Tomonori ^b   Kashiwagi, Atsunori ^b   Nakamura, Yasuyuki ^c   Kita, Yoshiyuki ^b   Tracy, Russell P ^d   Kuller, Lewis H ^a   Sekikawa, Akira ^a  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^c KYOTO WOMEN'S UNIVERSITY   (Japan)

^d UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

Epidemiology; Japan; PAI 1; Post war generation; US

Indexed keywords

ALCOHOL; C REACTIVE PROTEIN; GLUCOSE; INSULIN; LIPID; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD ANALYSIS; BODY MASS; CIGARETTE SMOKING; CONTROLLED STUDY; DRINKING BEHAVIOR; HUMAN; JAPAN; LIFESTYLE; MALE; NORMAL HUMAN; PHYSICAL EXAMINATION; QUESTIONNAIRE; UNITED STATES;

ADULT; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN; JAPAN; MALE; MIDDLE AGED; OBESITY; PLASMINOGEN ACTIVATOR INHIBITOR 1; RISK FACTORS; SMOKING; TRIGLYCERIDES; UNITED STATES;

EID: 33646121504     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2005.10.015     Document Type: Article

References (37)

1. Kohler H.P., and Grant P.J. Plasminogen activator inhibitor type 1 and coronary artery disease. N. Engl. J. Med. 342 (2000) 1792-1801
2. Pepper M.S. Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler. Thromb. Vasc. Biol. 21 (2001) 1104-1117
3. Sobel B.E. Increased plasminogen activator inhibitor-1 and vasculopathy. A reconcilable paradox. Circulation 99 (1999) 2496-2498
4. Juhan-Vague I., Roul C., Alessi M.C., Ardissone J.P., Heim M., and Vague P. Increased plasminogen activator inhibitor activity in non-insulin dependent diabetic patients-relationship with plasma insulin. Thromb. Haemost. 61 (1989) 370-373
5. Festa A., D'Agostino Jr. R., Tracy R.P., and Haffner S.M. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type II diabetes: the insulin resistance atherosclerosis study. Diabetes 51 (2002) 1131-1137
6. Festa A., D'Agostino Jr. R., Rich S.S., Jenny N.S., Tracy R.P., and Haffner S.M. Promoter (4G/5G) plasminogen activator inhibitor-1 genotype and plasminogen activator inhibitor-1 levels in blacks, Hispanics, and non-Hispanic whites: the insulin resistance atherosclerosis study. Circulation 107 (2003) 2422-2427
7. Iso H., Folsom A.R., Koike K.A., Sato S., Wu K.K., Shimamoto T., et al. Antigens of tissue plasminogen activator and plasminogen activator inhibitor-1: correlates in non-smoking Japanese and Caucasian men and women. Thromb. Haemost. 70 (1993) 475-480
8. Harris M.I. Non-insulin-dependent diabetes mellitus in black and white Americans. Diabetes Metab. Rev. 6 (1990) 71-90
9. Strategies to identify adults at high risk for type II diabetes: the diabetes prevention program. Diabetes Care 28 (2005) 138-144
10. Ministry of Labour, Health, and Welfare. National Cardivascular Disease Survey in 2000 (2001), Ministry of Labour, Health, and Welfare, Tokyo
11. Sekikawa A., Horiuchi B.Y., Edmundowicz D., Ueshima H., Curb J.D., Sutton-Tyrrell K., et al. A "natural experiment" in cardiovascular epidemiology in the early 21st century. Heart 89 (2003) 255-257
12. US Department of Health and Human Services, CfDCaP, NCfHS. National Health and Nutrition Examination Survey (2004), US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics, Hyattsville, MD
13. Sekikawa A., Ueshima H., Zaky R.W., Kadowaki T., Edmundowicz D., Okamura T., et al. Much lower prevalence of coronary calcium detected by electron-beam tomography among men aged 40-49 in Japan than in the US, despite a less favorable profile of major risk factors. Int. J. Epidemiol. 34 (2005) 173-179
14. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 18 (1972) 499-502
15. Bondar R.J., and Mead D.C. Evaluation of glucose-6-phosphate dehydrogenase from leuconostoc mesenteroides in the hexokinase method for determining glucose in serum. Clin. Chem. 20 (1974) 586-590
16. Declerck P.J., Alessi M.C., Verstreken M., Kruithof E.K., Juhan-Vague I., and Collen D. Measurement of plasminogen activator inhibitor-1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood 71 (1988) 220-225
17. Macy E.M., Hayes T.E., and Tracy R.P. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin. Chem. 43 (1997) 52-58
18. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., and Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
19. Minami J., Todoroki M., Yoshii M., Mita S., Nishikimi T., Ishimitsu T., et al. Effects of smoking cessation or alcohol restriction on metabolic and fibrinolytic variables in Japanese men. Clin. Sci. (Lond.) 103 (2002) 117-122
20. Festa A., D'Agostino Jr. R., Mykkanen L., Tracy R.P., Zaccaro D.J., Hales C.N., et al. Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance. The insulin resistance atherosclerosis study (IRAS). Arterioscler. Thromb. Vasc. Biol. 19 (1999) 562-568
21. Nakamura T., Adachi H., Hirai Y., Satoh A., Ohuchida M., and Imaizumi T. Association of plasminogen activator inhibitor-1 with insulin resistance in Japan where obesity is rare. Metabolism 52 (2003) 226-229
22. Sasaki A., Kurisu A., Ohno M., and Ikeda Y. Overweight/obesity, smoking, and heavy alcohol consumption are important determinants of plasma PAI-1 levels in healthy men. Am. J. Med. Sci. 322 (2001) 19-23
23. Juhan-Vague I., and Alessi M.C. PAI-1, obesity, insulin resistance and risk of cardiovascular events. Thromb. Haemost. 78 (1997) 656-660
24. Hamsten A., Wiman B., de Faire U., and Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N. Engl. J. Med. 313 (1985) 1557-1563
25. Landin K., Stigendal L., Eriksson E., Krotkiewski M., Risberg B., Tengborn L., et al. Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1. Metabolism 39 (1990) 1044-1048
26. Potter van Loon B.J., Kluft C., Radder J.K., Blankenstein M.A., and Meinders A.E. The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance. Metabolism 42 (1993) 945-949
27. Giltay E.J., Elbers J.M., Gooren L.J., Emeis J.J., Kooistra T., Asscheman H., et al. Visceral fat accumulation is an important determinant of PAI-1 levels in young, non-obese men and women: modulation by cross-sex hormone administration. Arterioscler. Thromb. Vasc. Biol. 18 (1998) 1716-1722
28. Skurk T., and Hauner H. Obesity and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-1. Int. J. Obes. Relat. Metab. Disord. 28 11 (2004) 1357-1364
29. Tanaka S., Horimai C., and Katsukawa F. Ethnic differences in abdominal visceral fat accumulation between Japanese, African-Americans, and Caucasians: a meta-analysis. Acta Diabetol. 40 (2003) S302-S304
30. Shimomura I., Funahashi T., Takahashi M., Maeda K., Kotani K., Nakamura T., et al. Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat. Med. 2 (1996) 800-803
31. Cigolini M., Targher G., Bergamo Andreis I.A., Tonoli M., Agostino G., and De Sandre G. Visceral fat accumulation and its relation to plasma hemostatic factors in healthy men. Arterioscler. Thromb. Vasc. Biol. 16 (1996) 368-374
32. Gottschling-Zeller H., Birgel M., Rohrig K., and Hauner H. Effect of tumor necrosis factor alpha and transforming growth factor beta 1 on plasminogen activator inhibitor-1 secretion from subcutaneous and omental human fat cells in suspension culture. Metabolism 49 (2000) 666-671
33. Panahloo A., Mohamed-Ali V., Lane A., Green F., Humphries S.E., and Yudkin J.S. Determinants of plasminogen activator inhibitor-1 activity in treated NIDDM and its relation to a polymorphism in the plasminogen activator inhibitor-1 gene. Diabetes 44 (1995) 37-42
34. Matsubara Y., Murata M., Isshiki I., Watanabe R., Zama T., Watanabe G., et al. Genotype frequency of plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism in healthy Japanese males and its relation to PAI-1 levels. Int. J. Hematol. 69 (1999) 43-47
35. Bastard J.P., Pieroni L., and Hainque B. Relationship between plasma plasminogen activator inhibitor-1 and insulin resistance. Diabetes Metab. Res. Rev. 16 (2000) 192-201
36. Abate N., and Chandalia M. The impact of ethnicity on type II diabetes. J. Diabetes Complications 17 (2003) 39-58
37. Balasubramanyam A., McKay S., Nadkarni P., Rajan A.S., Garza A., Pavlik V., et al. Ethnicity affects the post-prandial regulation of glycogenolysis. Am. J. Physiol. 277 (1999) E905-E914